Business
IN8bio to Present at Scientific Conferences in November: PEGS Europe, SITC and SNO
NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development
About this update from In8bio, Inc.
[{"type":"text","content":"NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, today announced presentations at three scientific conferences in November. Event:Protein & Antibody Engineering Summit (PEGS) EuropePresenter:Lawrence Lamb, Ph.D., Executive Vice President, Chief Scientific Officer and co-founder of IN8bioPresentation: A Pivotal Role for Concurrent Chemotherapy and γδ T Cell Therapy (Drug Resistant Therapy – DRI) in the Post-Induction Primary Disease Setting for Reducing the Immunosuppressive Properties of the Tumor MicroenvironmentDate:November 4Time:9 a.m. CETLocation:Hotel Arts Ritz Carleton, Barcelona Event:Society for Immunotherapy of Cancer (SITC) 36th Annual MeetingPresenter:Kate Rochlin, Ph.D., Vice President, Operations and Innovation at IN8bioPresentation:Poster 158: Chemotherapy Resistant Gamma Delta T-cell Immunotherapy can leverage synergistic ligand expression through combinational chemotherapy and PARP-inhibitor use to enhance tumor cell recognition & killingDate:November 13thTime:7 to 8:30 p.m. ESTLocation:Walter E. Washington Convention Center, Washington, D.C. Event:Society for Neuro-Oncology 26th Annual MeetingPresenterLei Ding, Ph.D., Staff Scientist – CAR T Lead, IN8bioPresentation:Poster: Dual chlorotoxin CAR and MGMT γδ T cells for drug resistant immunotherapy of glioblastoma multiformeDate:November 19Time:7:30 to 9:30 p.m. ESTLocation:Hynes Convention Center, Boston Event:Society for Neuro-Oncology 26th Annual MeetingSponsor:IN8bio-sponsored academic researchPresenter:Anita Hjelmeland, Ph.D., and Amber JonesPresentation:Poster: Enhancing Glioblastoma Cell Stress Response to Improve Gamma Delta T-Cell ImmunotherapyDate:November 19Time:7:30 to 9:30 p.m. ESTLocation:Hynes Convention Center, Boston About IN8bioIN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T-cell product candidates for solid and liquid tumors. Gamma-delta T-cells are a specialized population of T-cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio’s DeltEx platform employs allogeneic, autologous and genetically modified approaches to d...